Elanco Files Definitive Additional Proxy Materials

TL;DR

**Elanco just dropped definitive additional proxy materials, likely setting the stage for shareholder votes.**

AI Summary

Elanco Animal Health Inc. filed a DEFA14A on February 29, 2024, indicating definitive additional materials for a proxy statement. The filing includes a press release issued on the same date and lists Kathryn Grissom as the investor contact. This filing is related to their standard business operations as a pharmaceutical preparations company.

Why It Matters

This filing provides additional information to shareholders regarding upcoming votes or corporate actions, ensuring transparency and compliance with SEC regulations.

Risk Assessment

Risk Level: low — This is a routine regulatory filing for additional proxy materials, not indicating any immediate financial or operational risk.

Key Numbers

• 001-38661 — SEC File Number (Identifies the specific SEC registration for Elanco)
• 24704891 — FILM NUMBER (Internal SEC tracking number for the filing)
• 1231 — Fiscal Year End (Indicates Elanco's fiscal year ends in December)
• 2834 — SIC Code (Classifies Elanco as 'Pharmaceutical Preparations')

Key Players & Entities

• Elanco Animal Health Inc. (company) — Registrant
• Kathryn Grissom (person) — Investor Contact
• February 29, 2024 (date) — Filing Date
• Greenfield, IN (company) — Business Address City/State
• 877-352-6261 (company) — Business Phone

FAQ

From the Filing

0001104659-24-029437.txt : 20240229 0001104659-24-029437.hdr.sgml : 20240229 20240229170317 ACCESSION NUMBER: 0001104659-24-029437 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20240229 DATE AS OF CHANGE: 20240229 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 24704891 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 DEFA14A 1 tm247639d1_defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material under §240.14a-12 Elanco Animal Health Incorporated (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee paid previously with preliminary materials. ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. On February 29, 2024, Elanco Animal Health Incorporated issued the following press release: Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom, +1.317.273.9284, kathryn.grissom@elancoah.com Media Contact: Colleen Parr Dekker, +1.317.989.7011, colleen.dekker@elancoah.com Joele Frank: Kelly Sullivan / Adam Pollack (212) 355-4449 Elanco Animal Health is Executing on Plan to Deliver for Shareholders Ancora Nominates Director Candidates Despite Elanco’s Meaningful Operational Progress and Good Faith Engagement with the Investor GREENFIELD, Ind. (February 29, 2024) – Elanco Animal Health Incorporated (NYSE: ELAN) today issued the following statement in response to the submission of four nominees to the Company’s Board of Directors by Ancora Holdings Group, LLC (“Ancora”): The execution of Elanco’s Innovation, Portfolio and Productivity strategy, led by CEO Jeff Simmons, is working. Elanco has returned to growth and is progressing a robust and innovative pipeline that will generate further growth. Elanco’s commitment to the continued development of a strong and sustainable innovation pipeline is a multi-year process which is key to the Company’s future success. Importantly, shareholders have been rewarded. Elanco stock is up 39% over the past year, reaching a 52-week high earlier this week and significantly outperforming its peers. 1 The executive team and Board of Elanco welcome engagement with our shareholders and suggestions for improving the Company’s strategy and execution. Ancora has asked for just two meetings with the Company and the Company actively engaged with Ancora in both of those meetings. Since revealing its candidates in writing two weeks ago, Ancora has refused to allow the Elanco Board to meet those candidates. Instead, Ancora has demanded that the Board agree to add three of Ancora’s candidates, sight unseen, to the Elanco Board and to significantly overhaul the leadership of the Board and the Company. Our interest in meeting with their candidates still stands. Elanco has taken decisive actions to improve performance. Leadership has strengthened the Company’s focus through t